ArticleDrug and alcohol dependence2026
The effects of acute and repeated M1 agonist VU0364572 administration on cocaine-vs-food choice in male and female Sprague-Dawley rats.
Article in Drug and alcohol dependence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cocaine use disorder (CUD) represents a public health crisis for which there are currently no pharmacotherapies. Repeated administration of the muscarinic agonist xanomeline significantly decreased cocaine self-administration. However, the pharmacological mechanisms mediating xanomeline effects on cocaine reinforcement remain to be determined. The present aim was to determine whether selective M1 receptor activation with the M1 agonist VU0364572 was sufficient to attenuate cocaine-vs-food choice in male and female rats. Rats were trained to respond under a concurrent fixed-ratio (FR)5:FR5 schedule of intravenous cocaine infusions and liquid food during daily 2h sessions. VU0364572 (0.32-10mg/kg, IP) or vehicle was administered acutely before the cocaine choice session and VU034572 effects were observed for two-to-four weeks. Additionally, VU0364572 was administered using a 5-day dosing regimen to model clinical aspects of substance use disorder medication dosing regimens. During saline administration, cocaine maintained a dose-dependent increase in percent cocaine choice. Neither acute nor repeated VU0364572 administration up to 10mg/kg significantly altered cocaine choice in male and female rats. These results do not support VU0364572 as a candidate CUD pharmacotherapy and further suggest that xanomeline effectiveness to attenuate cocaine choice is not exclusively mediated by M1 receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.